Leadership

Frederic Cogny graduated with a Master’s in Applied Mathematics, specializing in Probabilities and Finance, from École Polytechnique in Paris.

Over the following 12 years, he honed his expertise in financial market modeling and quantitative trading while based in London, Tokyo, and Singapore. His most prominent role during this period was as Managing Director at Standard Chartered Bank, where he led diverse teams comprising traders, quantitative analysts, computer scientists, and IT engineers. His leadership focused on developing robust, efficient, and scalable analytics and trading frameworks.

In 2016, Frederic transitioned to the role of Chief Technology Officer at Novadiscovery. His initial task was to streamline and enhance the company’s research and development processes. He successfully built a dedicated team of technical and quantitative developers who created a sophisticated clinical trial simulation library.

Starting in 2020, Frederic took on additional responsibilities as Chief Product Officer, directing his focus towards product development and the architectural design of the Jinkō platform.

Now as Co-CEO alongside Grégoire Boutonnet & CPO of Nova In Silico, Frederic is dedicated to cultivating a cohesive and dynamic corporate culture, grounded in transparency and open communication. Together with Grégoire, he aims to foster a shared vision and purpose throughout the organization, ensuring all strategic initiatives align with their overarching mission.

As Co-CEO, Frederic is committed to driving results and efficiency across all facets of the company. He emphasizes the importance of engaged, well-informed teams that are integral to the organization’s success. Through collaborative leadership, Frederic and Grégoire ensure that Nova In Silico not only delivers high-quality scientific services but also thrives as a transparent and efficient organization, at the service of the sponsors and partners it serves.

Grégoire Boutonnet holds a Master’s degree in Fundamental Physics from Pierre and Marie Curie University.

With over two decades of experience in innovation, strategy, and digital entrepreneurship, Grégoire has a proven track record in building and scaling technology-driven companies. He began his career as the founder and CEO of Andrexen, an innovative Unified Communications cloud platform that he successfully expanded to over 10 countries worldwide. Following Andrexen’s acquisition by Cirpack in 2015, Grégoire took on the role of Chief Marketing and Product Officer, where he drove the company’s market positioning and product strategy.

Most recently, Grégoire served as Chief Strategy Officer at Experty.io, a blockchain-based knowledge sharing platform, where he focused on strategic growth initiatives and technological advancements.

As Co-CEO of Nova In Silico alongside Frederic Cogny and Chief Operating Officer, Grégoire is dedicated to ensuring the company’s operational excellence and strategic growth. He leads the business development & partnering team and the Modeling and Simulation (M&S) group, guiding it through its next phase of expansion. Grégoire’s leadership is characterized by a commitment to fostering innovation, efficiency, and a collaborative corporate culture.

Together with Frederic, Grégoire is devoted to cultivating a cohesive and dynamic organization grounded in transparency and open communication. They share a unified vision and purpose, ensuring that all strategic initiatives align with the company’s overarching mission. As Co-CEO, Grégoire emphasizes the importance of engaged, well-informed teams as critical to the organization’s success. Through their collaborative leadership, Grégoire and Frederic ensure that Nova In Silico delivers high-quality scientific services and thrives as a transparent and efficient organization, serving its sponsors and partners with excellence.

Julie holds two Master’s degrees: an MSc in Engineering from ESIL (France), majoring in Biotechnology, and an MSc in Business from Kedge Business School (France), majoring in International Business.

Julie began her career at the Trade Office of the French Embassy (Business France) in San Francisco, where she supported French biotech companies with their business development activities. Over the following six years, she built an extensive network in the life sciences industry across the US and Europe, gaining deep insights into a variety of innovative technologies.

In 2018, Julie returned to France and joined Novadiscovery to bolster the company’s sales activities. Her strategic vision and dedication to fostering client relationships were instrumental in driving the company’s growth.

By 2022, Julie was promoted to Vice President of Business Development and relocated back to the US. Now based in New York, she oversees global business development activities for Nova In Silico. Julie is dedicated to advancing the company’s mission by leveraging her expertise and network to forge strong partnerships and drive strategic initiatives.

Julie is committed to cultivating a cohesive and dynamic corporate culture at Nova In Silico, grounded in transparency and open communication. She emphasizes the importance of building engaged, well-informed teams that are integral to the company’s success. Through her leadership, Julie ensures that Nova In Silico not only excels in delivering high-quality scientific services but also thrives as a transparent and efficient organization, deeply committed to the success of its sponsors and partners.

Jim has spent over 15 years advancing systems biology modeling and advocating its adoption in pharmaceutical research. Prior to joining Novadiscovery he founded and ran a systems biology modeling consulting company, Clermont, Bosley LLC, serving major pharma/biotech. Prior to this, Jim served as Vice President of Modeling and Simulation at Rosa & Co., as Sr. Director of Software Products for Pharsight, as a Consulting Engineer for Entelos and as a Senior Engineer in DuPont’s BioChemical Science and Engineering group. He has written several articles and book chapters on QSP modeling.

Jim holds a PhD (Chem. E.) from the University of Texas at Austin, an MSc (E.E.) from the University of California-Irvine, and a BSc (Chem. E.) from the University of Wisconsin. He has taught courses, and is an affiliated faculty member, at the University of Delaware. As SVP Modeling and Simulation, Jim is supporting Nova In Silico’s expert modelers and programmers with both an understanding of the current state of the art technology, but also with innovative modeling ideas.

Emmanuel has more than 20 years of pharmaceutical industry and academic experience.

He is in charge of strengthening Nova In Silico’s relationships with pharmaceutical companies to understand their specific requirements for incorporating in silico technology into existing clinical development programs with a view to streamlining the development process through smaller, more effective clinical trials. He also works with regulatory authorities to develop protocols to aid pharmaceutical companies in including clinical simulation data into regulatory dossiers for new drug applications.

Jean-Pierre Boissel is a cardiologist by training and a pioneer in the field of in silico medicine.

He holds a distinguished career as an Emeritus Professor of Clinical Pharmacology at Claude Bernard University Lyon 1 and has served as a Scientific Director at the French Institute for Health and Medical Research (Inserm). Jean-Pierre was also an advisor to the General Surgeon.

As a co-founder and Chief Scientific Officer of Novadiscovery, Jean-Pierre has made significant contributions to the development and implementation of innovative solutions in therapeutic evaluation, cardiology, and systems medicine. He is recognized as one of the founding fathers of systems medicine, alongside renowned international experts.

Jean-Pierre’s career is marked by numerous groundbreaking achievements, including designing and directing the first randomized multicenter clinical trial in France for cardiology, pioneering methodologies in clinical trial design, and advancing the field of personalized medicine. His work has laid the foundation for many modern practices in clinical research and therapeutic evaluation.

In his role as Scientific Ambassador at Nova In Silico, Jean-Pierre actively promotes and evangelizes the in silico field globally. He provides invaluable scientific advisory support, leveraging his extensive experience and insights to guide the company’s research directions. Jean-Pierre’s influence extends beyond Nova In Silico, as he continues to inspire and educate the global scientific community on the transformative potential of in silico methodologies.

Claudio holds an MSc in Pharmacology and Clinical Trials Modeling from the University of Lyon, France. He joined Novadiscovery in 2012 and pursued a PhD in computational biology, playing a central role in many of Novadiscovery’s key modeling projects. His work includes contributions to EU-funded initiatives such as SysCLAD and PREDICTIV, along with collaborative projects with biotech firms and major pharmaceutical companies.

His expertise covers various aspects of systems biology, with a particular focus on immune system modeling and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD). More recently, Claudio has shifted his research emphasis to cancer modeling, specifically targeting non-small cell lung cancer (NSCLC). In 2023, he spearheaded the NSCLC project that achieved groundbreaking prospective predictions for phase III clinical trials, namely FLAURA2 and MARIPOSA.

As the Head of Content at NOVA, Claudio now manages a comprehensive library of models. His responsibilities encompass overseeing both internal development and external contributions, ensuring the platform remains at the forefront of computational biology innovation.